Ayala Pharmaceuticals, Inc. (ADXS)

Last Closing Price: 4.00 (2022-06-06)

Company Description

Ayala Pharmaceuticals Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. It also involved in developing proprietary Lm-based antigen delivery products for patients suffering from more common cancers. The company's lead candidates under development are AL102 and ADXS-504. Ayala Pharmaceuticals Inc., formerly known as Advaxis Inc., is based in REHOVOT, Israel.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $0.01M
Net Income (Most Recent Fiscal Year) $-48.07M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) --
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) --
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) --
Return on Assets (Trailing 12 Months) --
Current Ratio (Most Recent Fiscal Quarter) --
Quick Ratio (Most Recent Fiscal Quarter) --
Debt to Common Equity (Most Recent Fiscal Quarter) --
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $-2.06
Earnings per Share (Most Recent Fiscal Quarter) --
Earnings per Share (Most Recent Fiscal Year) --
Diluted Earnings per Share (Trailing 12 Months) --
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 42.63M
Free Float 42.36M
Market Capitalization $1.43M
Average Volume (Last 20 Days) 598.45
Beta (Past 60 Months) 1.18
Percentage Held By Insiders (Latest Annual Proxy Report) 0.63%
Percentage Held By Institutions (Latest 13F Reports) 7.18%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%